🔎 Trials Near Me

Pradžia › LOPSL › Džordžija

LOPSL klinikiniai tyrimai Džordžija

12 tyrimai dėl LOPSL ieško dalyvių vietose Džordžija.

Miestai Džordžija

Oficialus tyrimo tekstas (anglų kalba)

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

  • Research Site, Savannah
  • Research Site, Tucker
Renkami dalyviai3 fazė
Amžius nuo 40 iki 80 · Visoms lytims · Atnaujinta 2026-10-02 · NCT06283966

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype

  • Appalachian Clinical Research- Site Number : 8400060, Adairsville
Renkami dalyviai3 fazė
Amžius nuo 40 iki 80 · Visoms lytims · Atnaujinta 2026-10-01 · NCT07190222

To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment

  • Centricity Research Columbus, Rincon
Renkami dalyviai2 fazė
Amžius nuo 40 iki 85 · Visoms lytims · Atnaujinta 2026-09-30 · NCT07684820

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

  • Private Practice - Dr. David Kavtaradze- Site Number : 8400006, Cordele
  • Primeway Clinical Research- Site Number : 8400121, Fayetteville
Renkami dalyviai3 fazė
Amžius nuo 40 iki 80 · Visoms lytims · Atnaujinta 2026-09-22 · NCT07190209

A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.

  • Private Practice - Dr. David Kavtaradze- Site Number : 8400017, Cordele
Renkami dalyviai4 fazė
Amžius nuo 40 iki 85 · Visoms lytims · Atnaujinta 2026-09-22 · NCT07053423

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)

  • Research Site, Atlanta
  • Research Site, Cordele
  • Research Site, Decatur
  • ir dar 1
Renkami dalyviai3 fazė
Amžius nuo 40 iki 80 · Visoms lytims · Atnaujinta 2026-09-03 · NCT06878261

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

  • Research Site, Atlanta
  • Research Site, Lithonia
  • Research Site, Rincon
Renkami dalyviai3 fazė
Amžius nuo 40 iki 80 · Visoms lytims · Atnaujinta 2026-09-03 · NCT06883305

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

  • Cpcc-Research Llc, East Point
  • Centricity Research Rincon Pulmonology, Rincon
Renkami dalyviai2/3 fazė
Amžius nuo 35 iki 80 · Visoms lytims · Atnaujinta 2026-08-31 · NCT07363694

eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

  • GSK Investigational Site, Cordele
  • GSK Investigational Site, Dunwoody
Renkami dalyviai3 fazė
Amžius nuo 40 iki 75 · Visoms lytims · Atnaujinta 2026-07-28 · NCT07177339

Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH

  • Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur
Renkami dalyviai2 fazė
Amžius nuo 35 iki 89 · Visoms lytims · Atnaujinta 2026-05-15 · NCT05937854

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

  • GSK Investigational Site, Adairsville
  • GSK Investigational Site, Cordele
  • GSK Investigational Site, East Point
  • ir dar 1
Renkami dalyviai3 fazė
Amžius nuo 40 iki 80 · Visoms lytims · Atnaujinta 2026-04-09 · NCT06961214

Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening

  • SpeciCare, Inc, Gainesville
Renkami dalyviaiStebimasis tyrimas
Amžius 50 ir vyresni · Visoms lytims · Atnaujinta 2025-08-05 · NCT06122077

Iš ClinicalTrials.gov, duomenys gauti 2026-10-04. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.